imipenem + funobactam

Imipenem + XNW4107 (imipenem/cilastatin/funobactam) is an investigational, intravenously administered, broad-spectrum beta-lactam/beta-lactamase inhibitor (BL/BLI) combination therapy being developed by Evopoint Biosciences. The combination consists of imipenem (a carbapenem antibiotic), cilastatin (a renal dehydropeptidase-I inhibitor that prevents imipenem degradation in the kidneys), and funobactam (formerly XNW4107, a novel non-beta-lactam diazabicyclooctane serine beta-lactamase inhibitor). Funobactam provides potent inhibition against Ambler Class A, C, and D beta-lactamases, including OXA-type carbapenemases (such as OXA-23 and OXA-24) that commonly confer resistance in *Acinetobacter baumannii*. This triple-drug combination is designed to target the three major carbapenem-resistant organisms (CROs): carbapenem-resistant *A. baumannii* (CRAB), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), and carbapenem-resistant Enterobacteriaceae (CRE). It is currently in Phase III clinical development for the treatment of hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated urinary tract infections (cUTIs).

Other names

IMI-FUNIMI-XNW4107IMI-XNW-4107IMI-XNW 4107imipenem + cilastatin + funobactamimipenem + cilastatin + XNW4107imipenem + XNW4107imipenem/cilastatin/funobactamimipenem/cilastatin/XNW4107imipenem/funobactam